Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.
Junji Matsui, PhD
Advertisement
Articles by Junji Matsui, PhD
Advertisement
Latest Updated Articles
Anti-Proliferative Activity of Eribulin in Select Sarcoma Cell LinesPublished: May 5th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
2
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
3
NCCN Guidelines Recognize MammaPrint/BluePrint for Determining Anthracycline Benefit in Breast Cancer
4
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
5